

Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market By Type (Cervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment), By Region, And Segment Forecasts, 2025 - 2035

<https://marketpublishers.com/r/C7BA7E57C30CEN.html>

Date: April 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: C7BA7E57C30CEN

Abstracts

This report can be delivered to the clients within 3 Business days

Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Growth & Trends

The global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size is anticipated to reach USD 15,675.04 million by 2035 and is projected to grow at a CAGR of 5.90% from 2025 to 2035, according to a new report by Grand View Research, Inc. The market growth is driven by technological advancements, increased awareness, and a strong focus on preventive care. Despite persistent challenges such as disparities in healthcare access and the ongoing burden of cervical cancer, collaborative efforts among federal agencies, healthcare providers, and community organizations are fostering improved outcomes. Continued investment in early detection, innovative treatment options, and equitable healthcare access will be critical in reducing cervical cancer incidence and mortality. As the market expands, stakeholders must prioritize cost-effective solutions and innovative screening technologies to ensure comprehensive coverage across diverse populations.

The rapid adoption of advanced screening and treatment technologies has been a key driver of market expansion. For instance, in July 2024, women in Lakeland gained access to state-of-the-art cervical care at Aspirus Woodruff Clinic with the introduction of a Loop Electrosurgical Excision Procedure (LEEP) machine. This

technology marks a major step forward in the treatment of cervical dysplasia, with Dr. Joelle Wennlund, a Board-certified Gynecologist, emphasizing its critical role in cervical cancer prevention. Similarly, in January 2021, Pregna International Ltd. reinforced its position as a leader in women's healthcare by launching the CryoPop cryotherapy device. Developed in partnership with Jhpiego, CryoPop enhances accessibility to cervical pre-cancerous lesion treatment worldwide, aligning with WHO's global strategy for cervical cancer elimination.

One of the most significant growth opportunities in the cervical cancer screening and treatment industry is the development and implementation of cost-effective, accessible screening technologies. While Pap smears have historically played a crucial role in reducing cervical cancer rates in high-income countries, their reliance on specialized personnel and laboratory infrastructure limits their feasibility in resource-constrained settings. To address these challenges, the World Health Organization (WHO) has updated its guidelines to include more accessible screening methods, aiming to increase coverage and promote early detection in underserved regions. WHO's Global Strategy for the Elimination of Cervical Cancer seeks to screen 70% of women with a high-performance test at ages 35 and 45 by 2030. This initiative highlights the organization's commitment to expanding global screening programs, reinforcing the market's growth potential.

Traditional cervical cancer screening methods, such as Pap smears, have long been the gold standard. However, they are increasingly being supplemented by technological advancements such as liquid-based cytology and high-risk HPV DNA testing. These approaches improve sample quality, enhance diagnostic accuracy, and reduce turnaround time, making early detection more effective.

The integration of artificial intelligence (AI) in cervical cancer diagnostics has been a game changer, revolutionizing screening efficiency. AI-driven tools can now analyze cytological images with high precision, identifying abnormal cells that could indicate pre-cancerous or cancerous lesions. For example, AI-powered diagnostic systems can automatically evaluate digitized cytology slides, flagging potential abnormalities for further clinical review. This not only reduces human error but also expedites diagnostic processes, leading to faster medical interventions.

AI's impact extends beyond diagnostics to treatment planning. With machine learning and predictive analytics, healthcare providers can better assess lesion progression and offer personalized treatment approaches. Technologies such as LEEP and cryotherapy benefit significantly from AI precision, ensuring minimally invasive,

highly effective interventions with shorter recovery times. In regions where healthcare infrastructure is limited, AI-driven solutions help scale screening programs efficiently, making high-quality diagnostics and treatment more accessible.

Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market Report Highlights

Based on type, the cervical cancer screening segment led the market with the largest revenue share of 48.29% in 2024 and is expected to grow at the fastest CAGR during the forecast period. Cervical cancer screening is essential for early detection and prevention, utilizing a variety of devices and technologies to enhance accuracy, accessibility, and patient outcomes. Traditional Pap smear collection tools remain a cornerstone of screening, particularly in areas lacking advanced diagnostic infrastructure.

The cervical cancer diagnostics market is anticipated to witness a substantial CAGR during the forecast period, driven by advancements in biopsy devices and colposcopes, alongside increasing adoption and demand for these technologies. In December 2024, the Federal Capital Territory Administration introduced a colposcopy machine designed to enhance early detection and treatment of cervical cancer among women. This groundbreaking initiative is expected to revolutionize healthcare delivery in the region.

North America dominated the market with the largest revenue share of 41.17% in 2024. North America has made remarkable progress in reducing cervical cancer incidence and mortality over the past several decades, primarily through extensive cervical cancer screening programs. These initiatives rely heavily on Pap smears (cytology) and, increasingly, human papillomavirus (HPV) testing. However, despite high overall screening rates in many regions, disparities persist in screening participation and follow-up care, particularly among underserved populations. To address these gaps, healthcare

systems across North America are adopting innovative solutions. Recent FDA approvals for HPV self-collection tests, such as the cobas HPV and BD Onclarity HPV assays, present a promising alternative for women wh%li%may avoid traditional pelvic exams due t%li%discomfort, cultural sensitivities, or past trauma

Contents

CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
 - 1.1.1. Type
 - 1.1.2. Regional scope
 - 1.1.3. Estimates and forecast timeline.
- 1.2. Research Methodology
- 1.3. Information Procurement
 - 1.3.1. Purchased database.
 - 1.3.2. GVR's internal database
 - 1.3.3. Secondary sources
 - 1.3.4. Primary research
 - 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
 - 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
 - 1.6.1. Commodity flow analysis (Model 1)
 - 1.6.2. Approach 1: Commodity flow approach
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
 - 2.2.1. Type outlook
 - 2.2.2. Regional outlook
- 2.3. Competitive Insights

CHAPTER 3. CERVICAL CANCER SCREENING, DIAGNOSTICS, AND PRE-CANCEROUS DYSPLASIA LESION TREATMENT MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Dynamics
 - 3.1.1. Market driver analysis

- 3.1.2. Market restraint analysis
- 3.1.3. Market opportunities analysis
- 3.2. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Analysis Tools
 - 3.2.1. Industry Analysis - Porter's
 - 3.2.1.1. Supplier power
 - 3.2.1.2. Buyer power
 - 3.2.1.3. Substitution threat
 - 3.2.1.4. Threat of new entrant
 - 3.2.1.5. Competitive rivalry
 - 3.2.2. PESTEL Analysis
 - 3.2.2.1. Political landscape
 - 3.2.2.2. Economic landscape
 - 3.2.2.3. Social landscape
 - 3.2.2.4. Technological landscape
 - 3.2.2.5. Environmental landscape
 - 3.2.2.6. Legal landscape

CHAPTER 4. CERVICAL CANCER SCREENING, DIAGNOSTICS, AND PRE-CANCEROUS DYSPLASIA LESION TREATMENT MARKET, QUALITATIVE DATA ANALYSIS

- 4.1. Screening Guidelines for Cervical Cancer
- 4.2. Utilization of Cervical Cancer Screening
- 4.3. WHO and Other Policy Board Positions
- 4.4. Barriers to Cervical Cancer Screening

CHAPTER 5. CERVICAL CANCER SCREENING, DIAGNOSTICS, AND PRE-CANCEROUS DYSPLASIA LESION TREATMENT MARKET, MARKET DEVELOPMENTS ANALYSIS

- 5.1. Emerging Technology and Innovation Trends
- 5.2. Reimbursement Landscape
- 5.3. Incidence and Prevalence of Cervical Cancer
- 5.4. Total Eligible Population
- 5.5. Assessing Trends in HPV-Vaccinated Populations

CHAPTER 6. CERVICAL CANCER SCREENING, DIAGNOSTICS, AND PRE-CANCEROUS DYSPLASIA LESION TREATMENT MARKET: TYPE ESTIMATES &

TREND ANALYSIS

- 6.1. Type Market Share, 2024 & 2035
- 6.2. Segment Dashboard
- 6.3. Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market by Type Outlook
- 6.4. Cervical Cancer Screening
 - 6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.4.2. Pap Smear Collection Devices
 - 6.4.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.4.3. HPV Testing Platforms
 - 6.4.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.4.4. Cytobrush
 - 6.4.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.4.5. Self-collection kits
 - 6.4.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.4.6. Others
 - 6.4.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
- 6.5. Cervical Cancer Diagnostics
 - 6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.5.2. Colposcopes
 - 6.5.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.5.3. Cervical Biopsy Devices
 - 6.5.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.5.4. Colposcopes with AI Imaging (Digital)
 - 6.5.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.5.5. Others
 - 6.5.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
- 6.6. Pre-cancerous Lesion Treatment
 - 6.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.6.1.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.6.2. LEEP (loop electrosurgical excision procedure) Machine
 - 6.6.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.6.3. Cryotherapy
 - 6.6.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.6.4. Thermal Ablation
 - 6.6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
 - 6.6.5. Others
 - 6.6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)

CHAPTER 7. CERVICAL CANCER SCREENING, DIAGNOSTICS, AND PRE-CANCEROUS DYSPLASIA LESION TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT, BY TYPE, BY END USE

7.1. Regional Market Share Analysis, 2024 & 2035

7.2. Regional Market Dashboard

7.3. Global Regional Market Snapshot

7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2035:

7.5. North America

7.5.1. U.S.

7.5.1.1. Key country dynamics

7.5.1.2. Regulatory framework/ reimbursement structure

7.5.1.3. Competitive scenario

7.5.1.4. U.S. market estimates and forecasts, 2018 to 2035 (USD Million)

7.5.2. Canada

7.5.2.1. Key country dynamics

7.5.2.2. Regulatory framework/ reimbursement structure

7.5.2.3. Competitive scenario

7.5.2.4. Canada market estimates and forecasts, 2018 to 2035 (USD Million)

7.5.3. Mexico

7.5.3.1. Key country dynamics

7.5.3.2. Regulatory framework/ reimbursement structure

7.5.3.3. Competitive scenario

7.5.3.4. Mexico market estimates and forecasts, 2018 to 2035 (USD Million)

7.6. Europe

7.6.1. UK

7.6.1.1. Key country dynamics

7.6.1.2. Regulatory framework/ reimbursement structure

7.6.1.3. Competitive scenario

7.6.1.4. UK market estimates and forecasts, 2018 to 2035 (USD Million)

7.6.2. Germany

7.6.2.1. Key country dynamics

7.6.2.2. Regulatory framework/ reimbursement structure

7.6.2.3. Competitive scenario

7.6.2.4. Germany market estimates and forecasts, 2018 to 2035 (USD Million)

7.6.3. France

7.6.3.1. Key country dynamics

7.6.3.2. Regulatory framework/ reimbursement structure

- 7.6.3.3. Competitive scenario
- 7.6.3.4. France market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.6.4. Italy
 - 7.6.4.1. Key country dynamics
 - 7.6.4.2. Regulatory framework/ reimbursement structure
 - 7.6.4.3. Competitive scenario
 - 7.6.4.4. Italy market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.6.5. Spain
 - 7.6.5.1. Key country dynamics
 - 7.6.5.2. Regulatory framework/ reimbursement structure
 - 7.6.5.3. Competitive scenario
 - 7.6.5.4. Spain market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.6.6. Norway
 - 7.6.6.1. Key country dynamics
 - 7.6.6.2. Regulatory framework/ reimbursement structure
 - 7.6.6.3. Competitive scenario
 - 7.6.6.4. Norway market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.6.7. Sweden
 - 7.6.7.1. Key country dynamics
 - 7.6.7.2. Regulatory framework/ reimbursement structure
 - 7.6.7.3. Competitive scenario
 - 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.6.8. Denmark
 - 7.6.8.1. Key country dynamics
 - 7.6.8.2. Regulatory framework/ reimbursement structure
 - 7.6.8.3. Competitive scenario
 - 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.7. Asia Pacific
 - 7.7.1. Japan
 - 7.7.1.1. Key country dynamics
 - 7.7.1.2. Regulatory framework/ reimbursement structure
 - 7.7.1.3. Competitive scenario
 - 7.7.1.4. Japan market estimates and forecasts, 2018 to 2035 (USD Million)
 - 7.7.2. China
 - 7.7.2.1. Key country dynamics
 - 7.7.2.2. Regulatory framework/ reimbursement structure
 - 7.7.2.3. Competitive scenario
 - 7.7.2.4. China market estimates and forecasts, 2018 to 2035 (USD Million)
 - 7.7.3. India

- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. India market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.7.4. Australia
 - 7.7.4.1. Key country dynamics
 - 7.7.4.2. Regulatory framework/ reimbursement structure
 - 7.7.4.3. Competitive scenario
 - 7.7.4.4. Australia market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.7.5. South Korea
 - 7.7.5.1. Key country dynamics
 - 7.7.5.2. Regulatory framework/ reimbursement structure
 - 7.7.5.3. Competitive scenario
 - 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.7.6. Thailand
 - 7.7.6.1. Key country dynamics
 - 7.7.6.2. Regulatory framework/ reimbursement structure
 - 7.7.6.3. Competitive scenario
 - 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.8. Latin America
 - 7.8.1. Brazil
 - 7.8.1.1. Key country dynamics
 - 7.8.1.2. Regulatory framework/ reimbursement structure
 - 7.8.1.3. Competitive scenario
 - 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2035 (USD Million)
 - 7.8.2. Argentina
 - 7.8.2.1. Key country dynamics
 - 7.8.2.2. Regulatory framework/ reimbursement structure
 - 7.8.2.3. Competitive scenario
 - 7.8.2.4. Argentina market estimates and forecasts, 2018 to 2035 (USD Million)
- 7.9. MEA
 - 7.9.1. South Africa
 - 7.9.1.1. Key country dynamics
 - 7.9.1.2. Regulatory framework/ reimbursement structure
 - 7.9.1.3. Competitive scenario
 - 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2035 (USD Million)
 - 7.9.2. Saudi Arabia
 - 7.9.2.1. Key country dynamics
 - 7.9.2.2. Regulatory framework/ reimbursement structure

7.9.2.3. Competitive scenario

7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2035 (USD Million)

7.9.3. UAE

7.9.3.1. Key country dynamics

7.9.3.2. Regulatory framework/ reimbursement structure

7.9.3.3. Competitive scenario

7.9.3.4. UAE market estimates and forecasts, 2018 to 2035 (USD Million)

7.9.4. Kuwait

7.9.4.1. Key country dynamics

7.9.4.2. Regulatory framework/ reimbursement structure

7.9.4.3. Competitive scenario

7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2035 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments & Impact Analysis, By Key Market Participants

8.2. Company/Competition Categorization

8.3. Key company market share/position analysis, 2024

8.4. Company Profiles

8.4.1. F. Hoffmann-La Roche

8.4.1.1. Company overview

8.4.1.2. Financial performance

8.4.1.3. Technology Type benchmarking

8.4.1.4. Strategic initiatives

8.4.2. BD

8.4.2.1. Company overview

8.4.2.2. Financial performance

8.4.2.3. Technology Type benchmarking

8.4.2.4. Strategic initiatives

8.4.3. Abbott

8.4.3.1. Company overview

8.4.3.2. Financial performance

8.4.3.3. Technology Type benchmarking

8.4.3.4. Strategic initiatives

8.4.4. QIAGEN

8.4.4.1. Company overview

8.4.4.2. Financial performance

8.4.4.3. Technology Type benchmarking

8.4.4.4. Strategic initiatives

- 8.4.5. Hologic, Inc.
 - 8.4.5.1. Company overview
 - 8.4.5.2. Financial performance
 - 8.4.5.3. Technology Type benchmarking
 - 8.4.5.4. Strategic initiatives
- 8.4.6. CooperSurgical Inc.
 - 8.4.6.1. Company overview
 - 8.4.6.2. Financial performance
 - 8.4.6.3. Technology Type benchmarking
 - 8.4.6.4. Strategic initiatives
- 8.4.7. MedGyn Products, Inc
 - 8.4.7.1. Company overview
 - 8.4.7.2. Financial performance
 - 8.4.7.3. Technology Type benchmarking
 - 8.4.7.4. Strategic initiatives
- 8.4.8. WISAP Medical Technology GmbH
 - 8.4.8.1. Company overview
 - 8.4.8.2. Financial performance
 - 8.4.8.3. Technology Type benchmarking
 - 8.4.8.4. Strategic initiatives
- 8.4.9. Liger Medical
 - 8.4.9.1. Company overview
 - 8.4.9.2. Financial performance
 - 8.4.9.3. Technology Type benchmarking
 - 8.4.9.4. Strategic initiatives
- 8.4.10. Utah Medical Products, Inc.
 - 8.4.10.1. Company overview
 - 8.4.10.2. Financial performance
 - 8.4.10.3. Technology Type benchmarking
 - 8.4.10.4. Strategic initiatives

I would like to order

Product name: Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market By Type (Cervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment), By Region, And Segment Forecasts, 2025 - 2035

Product link: <https://marketpublishers.com/r/C7BA7E57C30CEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7BA7E57C30CEN.html>